Clinical Trial Update: Efficacy and Safety of Fluvastatin Sodium Extended Release Tablets 80 mg Once Daily in Chinese Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy and safety of fluvastatin sodium extended-release 80 mg once daily in Chinese patients with primary hypercholesterolemia o…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia
• Mixed Dyslipidemia

Drugs mentioned

• Fluvastatin sodium extended-release tablets 80 mg (fluvastatin)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Lipid Metabolism Disorders | Phase 4 | Status: COMPLETED | Results posted: 2014-06-11